Literature DB >> 2375402

Adrenergic and cholinergic responsiveness of isolated canine bronchial arteries.

S T O'Rourke1, P M Vanhoutte.   

Abstract

The purpose of this study was to characterize the adrenergic and cholinergic responsiveness of isolated rings of canine bronchial arteries. Electrical stimulation of the vessels produced frequency-dependent contractions that were inhibited by phenoxybenzamine, tetrodotoxin, and phentolamine but not by atropine. Norepinephrine caused concentration-dependent contractions of the rings; the concentration-response curve to norepinephrine was shifted to the right by phentolamine and prazosin, whereas rauwolscine had no effect. Isoproterenol, norepinephrine, tyramine, and electrical stimulation (in the presence of phentolamine) failed to elicit relaxation in rings contracted with prostaglandin F2 alpha. Contracted rings relaxed to acetylcholine in an endothelium- and concentration-dependent manner. At concentrations up to 10(-4) M, acetylcholine did not evoke contractions in these tissues. Endothelium-dependent relaxation to acetylcholine was inhibited by atropine and 4-diphenyl-acetoxy-N-methyl piperidine methiodine but not by pirenzepine. These results suggest that alpha 1-adrenoceptors mediate contraction to norepinephrine, and M3-muscarinic receptors mediate endothelium-dependent relaxation to acetylcholine in the canine bronchial artery. Moreover, the smooth muscle of these vessels does not respond directly to beta-adrenergic- or cholinergic-receptor stimulation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2375402     DOI: 10.1152/ajpheart.1990.259.1.H156

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  2 in total

1.  Attenuation of contractions to acetylcholine in canine bronchi by an endogenous nitric oxide-like substance.

Authors:  Y Gao; P M Vanhoutte
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

2.  Adrenergic mechanisms in canine nasal venous systems.

Authors:  Min Wang; Mary A Lung
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.